Thrombocytopenia Clinical Trial
Official title:
A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Verified date | November 2022 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must complete the taper or discontinuation of medical SOC for ITP as soon as medically feasible after the initiation of romiplostim. After the completion or discontinuation of the study treatment period, any participant who does not transfer in to another romiplostim study will complete a 6-month Safety Follow-up period.
Status | Completed |
Enrollment | 234 |
Est. completion date | May 11, 2009 |
Est. primary completion date | November 7, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is = 18 years of age - Subject has a diagnosis of Idiopathic Thrombocytopenia Purpura (ITP) according to the American Society of Hematology (ASH) guidelines - If subject is > 60 years of age, subject has a written bone marrow biopsy report confirming the diagnosis of ITP - Subject has received at least 1 prior therapy for ITP - Subject has a platelet count < 50,000 or their platelet count falls to < 50,000 during or after a clinically-indicated taper or discontinuation of current ITP therapy - Before any study-specific procedure, the appropriate written informed consent must be obtained Exclusion Criteria: - Subject has had a splenectomy for any reason - Subject has an active malignancy - Subject has a history of cancer, other than basal cell carcinoma or cervical carcinoma in situ, with treatment or active disease within 5 years - Subject has a known history of bone marrow stem cell disorder - Subject has participated in any study evaluating polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), AMG 531, or a thrombopoietic protein - Subject is receiving other investigational agents or procedures - Subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study - Subject is pregnant or breast feeding - Subject is not using adequate contraceptive precautions - Subject has known sensitivity to any recombinant E. coli-derived product - Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and does not have a legally acceptable representative - Subject has any kind of disorder that compromises the ability of the subject to comply with study procedures |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Amgen |
Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012 May;87(5):558-61. doi: 10.1002/ajh.23163. Epub 2012 Mar 28. — View Citation
Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 Nov 11;363(20):1889-99. doi: 10.1056/NEJMoa1002625. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Splenectomy During 52-Week Treatment Period | Occurrence of a splenectomy. Participants who discontinued study during the treatment period prior to reporting a splenectomy were considered as having had a splenectomy. | 52 weeks | |
Primary | Number of Participants With Treatment Failure During 52-Week Treatment Period | Treatment failure was defined by platelet counts = 20 x 10^9/L for 4 consecutive weeks at the highest recommended dose and schedule, a major bleeding event, or change in therapy due to an intolerable side effect or bleeding symptom. | 52 weeks | |
Secondary | Time to Splenectomy | Time to splenectomy in days calculated from date of randomization to date of splenectomy, or censored at date of end of treatment visit if no splenectomy was done during treatment period. | 52 weeks | |
Secondary | Percentage of Participants With Platelet Response | Platelet response was defined as platelet counts > 50 x 10^9/L, measured at each study visit (excluding those within 8 weeks of prior rescue medication use) up to the time of splenectomy or the end of initial treatment period, whichever occurred first. | Weeks 1-8, and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 | |
Secondary | Change in ITP-PAQ Physical Health Domain of Symptoms | Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of symptoms. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life.
Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates. |
Baseline and 52 weeks | |
Secondary | Change in ITP-PAQ Physical Health Domain of Fatigue | Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of fatigue. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates. | Baseline and 52 weeks | |
Secondary | Change in ITP-PAQ Physical Health Domain of Bother | Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of bother. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates. | Baseline and 52 weeks | |
Secondary | Change in ITP-PAQ Physical Health Domain of Activity | Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of activity. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life.
Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates. |
Baseline and 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT03633019 -
High-dose Use of rhTPO in CIT Patients
|
Phase 4 | |
Recruiting |
NCT06087198 -
Clinical Performance Evaluation of T-TAS®01 HD Chip
|
||
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Active, not recruiting |
NCT03688191 -
Study of Sirolimus in CTD-TP in China
|
Phase 4 | |
Completed |
NCT02845609 -
Efficacy of Sialic Acid GNE Related Thrombocytopenia
|
Phase 2 | |
Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
Unknown status |
NCT01196884 -
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
|
||
Terminated |
NCT01368211 -
Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)
|
Phase 2/Phase 3 | |
Completed |
NCT01356576 -
Effect of Hemodialysis Membranes on Platelet Count
|
N/A | |
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A | |
Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
Not yet recruiting |
NCT06036966 -
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
|
Phase 2 | |
Completed |
NCT01791101 -
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
|
Phase 2 | |
Recruiting |
NCT06053021 -
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
|
N/A | |
Recruiting |
NCT03701217 -
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05958511 -
Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients
|